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Abstract 25 
Objective: To investigate the inhibitory effects and the regulatory mechanisms of HDAC 26 
inhibitors on mechanical stress-induced gene expression of RUNX-2 and ADAMTS-5 in 27 
human chondrocytes 28 
Methods: Human chondrocytes were seeded in stretch chambers at a concentration of 5 29 
× 104 cells/chamber. Cells were pre-incubated with or without HDAC inhibitors (MS-275 30 
or Trichostatin A; TSA) for 12 h, followed by uniaxial cyclic tensile strain (CTS) (0.5 Hz, 31 
10% elongation), which was applied for 30 min using the ST-140-10 system (STREX, 32 
Osaka, Japan). Total RNA was extracted and the expression of RUNX-2, ADAMTS-5, 33 
MMP-3, and MMP-13 at the mRNA and protein levels were examined by real-time PCR 34 
and immunocytochemistry, respectively. The activation of diverse mitogen-activated 35 
protein kinase (MAPK) pathways with or without HDAC inhibitors during CTS was 36 
examined by western blotting. 37 
Results: HDAC inhibitors (TSA: 10 nM, MS-275: 100 nM) suppressed CTS-induced 38 
expression of RUNX-2, ADAMTS-5, and MMP-3 at both the mRNA and protein levels 39 
within 1 h. CTS-induced activation of p38, ERK, and JNK MAPKs was downregulated 40 
by both HDAC inhibitors. 41 
Conclusion: The CTS-induced expression of RUNX-2 and ADAMTS-5 was suppressed 42 
by HDAC inhibitors via the inhibition of the MAPK pathway activation in human 43 
chondrocytes. The results of the current study suggested a novel therapeutic role for 44 
HDAC inhibitors against degenerative joint disease such as osteoarthritis. 45 
 46 
 47 
 48 
 49 
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Introduction 50 
The main extracellular matrix (ECM) macromolecules of the articular cartilage 51 
are type II collagen and aggrecan [1, 2]. The disease progression of osteoarthritis (OA) is 52 
a highly complicated process involving multiple events, including aggrecan and type II 53 
collagen degradation that is caused by increased cleavage due to the activation of 54 
proteolytic enzymes, such as matrix metalloproteinases (MMPs) and a disintegrin and 55 
metalloproteinase with thrombospondin motifs (ADAMTSs). MMPs are induced in 56 
chondrocytes in response to various stimuli, such as proinflammatory cytokines or 57 
mechanical load, and then cleave a variety of ECM components, including proteoglycans, 58 
collagens, and procollagens [3]. Currently, ADAMTS-5 is the most efficient in terms of 59 
its proteolytic activity, as previous studies have suggested that ADAMTS-5 may play a 60 
pivotal role in the OA pathogenesis [4-6]. Loss of type II collagen and aggrecan 61 
degradation are two of the earliest events in the course of OA following mechanical injury 62 
of collagen fibrils [7]. 63 
Runt-related transcription factor (RUNX) family members regulate gene 64 
expression involved in cellular differentiation and cell cycle progression. RUNX-2 plays 65 
a key role in bone mineralization by stimulating osteoblast differentiation [8] and 66 
contributes to OA pathogenesis through chondrocyte hypertrophy and matrix breakdown 67 
after the initiation of joint instability [9]. Mitogen-activated protein kinase (MAPK) 68 
pathways play essential regulatory roles in early osteoblast differentiation in response to 69 
mechanical stress via the activation of RUNX-2 [10-13]. Several MAPKs, such as 70 
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 71 
MAPK (p38), have been reported to play a role in osteoblast differentiation [14-16]. We 72 
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previously reported that mechanical stress-induced expression of RUNX-2 and 73 
ADAMTS-5 is regulated by p38 in a SW1353 human chondrosarcoma cell line [17].  74 
Recent reports have shown that the epigenetic regulation of gene expression may 75 
be a novel therapeutic approach for arthritis [18, 19]. Histone deacetylase (HDAC) 76 
inhibitors have emerged as a promising new class of anticancer drugs based on their 77 
ability to activate a variety of genes implicated in the regulation of cell survival, 78 
proliferation, and apoptosis [20-23]. We previously showed that the modification of 79 
histone acetylation by HDAC inhibitors can successfully ameliorate synovial 80 
inflammation via the upregulation in synovial fibroblasts of cell cycle regulators in an 81 
animal arthritis model [24]. Interestingly, the expression of MMP-3 and MMP-13 were 82 
effectively downregulated, leading to the abrogation of cartilage destruction in mouse 83 
models [25]. However, whether HDAC inhibitors directly contribute to the prevention of 84 
cartilage matrix degradation has not been fully elucidated. 85 
In the current study, the effect of HDAC inhibitors on the mechanical stress-86 
induced gene expression of RUNX-2, ADAMTS-5, and MMP-3 was examined in vitro 87 
using human chondrocytes. Our findings provide further evidence that HDAC inhibitors 88 
may have a role in the suppression of cartilage degeneration through the inhibition of 89 
mechanical stress-induced proteolytic enzymes.  90 
  91 
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Materials and methods 92 
Cells and cell culture  93 
Normal human articular chondrocytes (NHAC-kn cells) obtained from a 45-year-94 
old male were purchased from Lonza (Walkersville, MD, USA). Cells were cultured in 95 
15 mL of chondrocyte basal medium (CBM; Lonza) containing supplements and several 96 
growth factors [Revitropin - long R3 insulin-like growth factor (R3-IGF-1), basic 97 
fibroblast growth factor (bFGF), tranferrin, insulin, fetal bovine serum (FBS), and 98 
gentamicin/amphotericin-B; CGMTM singleQuots®, Lonza] and were then subcultured at 99 
split ratios of 1:3 using trypsin plus ethylenediaminetetraacetic acid (EDTA) every 6−7 100 
days. The medium was changed every 3 days. The cells were subcultured for two passages 101 
and cells at the third passage were used for experiments within 2 weeks after starting the 102 
cell cultures. For all experiments, human chondrocytes were transferred to serum-free α-103 
modified minimum essential medium (MEMα, Wako, Osaka, Japan) for 12 h before 104 
exposure to different stimuli. 105 
Cyclic tensile strain on chondrocytes cultured in monolayer  106 
Human chondrocytes were seeded in stretch chambers coated with fibronectin at 107 
a concentration of 5 × 104 cells/chamber; each chamber had a culture surface of 2 × 2 cm. 108 
Mechanical stresses were applied using the ST-140-10 mechanical stretch system 109 
(STREX, Osaka, Japan). The chamber was attached to the stretching apparatus, which 110 
has one fixed side opposite a movable side that can be driven by a computer-controlled 111 
motor. By using this apparatus, the entire silicon membrane area and almost all cells on 112 
the stretch chambers can be stretched uniformly [26, 27]. After culturing for 48 h, the 113 
cells increased to 60% confluence in the chamber. In the current study, a cyclic tensile 114 
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strain (CTS; 0.5 Hz, 10% elongation) was applied for 30 min according to our previous 115 
study [17].  To apply mechanical stress, cells were cultured in stretch chambers, and set 116 
on the ST-140-10 system in an incubator (Supplemental Fig. 1). Cells without mechanical 117 
stress were seeded on the same chambers, and used as controls.  118 
Treatment with HDAC inhibitors 119 
We used two HDAC inhibitors: trichostatin A (TSA; Sigma-Aldrich, Oakville, 120 
Ontario, Canada), a general HDAC inhibitor, and MS-275 (Cayman Chemical, Ann 121 
Arbor, MI, USA), a class I HDAC specific inhibitor.  All inhibitors were used at various 122 
concentrations for 12 h before CTS. TSA and MS-275 were dissolved in dimethyl 123 
sulfoxide (DMSO) and then diluted with phosphate buffered saline (PBS) to a working 124 
concentration up to 500 μM.  125 
Cell proliferation assay 126 
Cells were incubated with or without TSA and MS-275 at various concentrations 127 
(10, 100, 500 nM) for 12 h before CTS. Cell viability was evaluated at 1 h after CTS, 128 
using the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 129 
bromide, a yellow tetrazole) assay (Chemicon, Temecula, CA, USA) according to the 130 
manufacturer’s instructions. The experiments were repeated 6 times. 131 
RT-PCR and real-time PCR analysis 132 
We examined the effect of CTS and HDAC inhibitors on RUNX-2, MMP-3, 133 
MMP-13, and ADAMTS-5 expression in human chondrocytes by reverse transcription 134 
polymerase chain reaction (RT-PCR) and real-time PCR. The half-life of the type II 135 
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collagen α1 chain (COL2A1) mRNA is reported to be approximately 15 h [28, 29]; 136 
therefore, we used COL2A1 expression using real-time PCR at 15 h after CTS as a 137 
positive control. 138 
After stimulation, the cells were washed with PBS, and total RNA was extracted 139 
using ISOGEN reagent (Nippon Gene, Toyama, Japan), according to the manufacturer’s 140 
protocol. The concentration and purity of total RNA were assayed by spectrophotometry. 141 
To make complementary DNA (cDNA), 1 µg of total RNA was reverse transcribed using 142 
ReverTra Ace, a Moloney murine leukemia virus reverse transcriptase, with Oligo-dT 143 
primers, according to the manufacturer’s instructions (TOYOBO, Tokyo, Japan). The 144 
cDNA was PCR-amplified using 10 pmol of each specific primer and ExTaq DNA 145 
polymerase (TAKARA BIO, Shiga, Japan). The sequences of the oligonucleotide primers 146 
are shown in Table 1 (COL2A1, RUNX-2, MMP-3, MMP-13, glyceraldehyde-3-147 
phosphate dehydrogenase (G3PDH) and ADAMTS-5). For all RT-PCR fragments, the 148 
reactions were allowed to proceed for 35 cycles (30 cycles for G3PDH) in a T3000 149 
thermocycler (Biometra, Göttingen, Germany).  150 
Real-time PCR was performed using an Mx3000P QPCR System (Agilent 151 
Technologies, Santa Clara, CA, USA) with Brilliant III Ultra-Fast SYBR Green QPCR 152 
Master Mix. The PCR mixture was in a total volume of 20 µL and consisted of 1× SYBR 153 
Green PCR Master Mix, which included DNA polymerase, SYBR Green dye, dNTPs 154 
(including dUTP), PCR buffer, 10 pmol each of the forward and reverse primers, and 155 
cDNA of the samples. Amplification of a housekeeping gene, G3PDH, was used for 156 
normalizing the efficiency of cDNA synthesis and the amount of RNA. We calculated the 157 
final expression levels by dividing the expression level of RUNX-2, MMP-3, MMP-13, 158 
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and ADAMTS-5 by the expression level of G3PDH. Each value obtained for the control 159 
cells (un-stretched cells without HDAC inhibitors) was set to 1.  160 
Immunocytochemistry 161 
 Immunocytochemistry was used to observe the mechanical-stress induced 162 
expression and localization of RUNX-2 and ADAMTS-5. Cells were loaded for 30 min 163 
by CTS (0.5 Hz, 10% elongation) with or without HDAC inhibitors (TSA: 10 nM, MS-164 
275: 100 nM) and then fixed with 1% paraformaldehyde solution. The chambers were 165 
incubated with anti-RUNX-2 antibody (10 mg/mL, ab76956, Abcam, Cambridge, UK) 166 
and anti-human ADAMTS-5 antibody (10 mg/mL, R&D Systems, Minneapolis, MN, 167 
USA) for 120 min at room temperature. Bovine serum albumin-containing solutions 168 
without primary antibodies were used as negative controls. We used Alexa Fluor 488-169 
conjugated antibody (10 mg/mL, anti-mouse), Alexa Fluor 568-conjugated phalloidin (2 170 
mg/mL, Molecular Probes, Eugene, OR, USA), and Hoechst 33342 (1 mg/mL, ICN 171 
Biomedicals, Aurora, OH, USA) as secondary antibodies. Samples were evaluated under 172 
a fluorescence microscope (Leica, Wetzlar, Germany), and protein expression was 173 
evaluated by the positive cell ratio of RUNX-2 or ADAMTS-5 (number of positive cells 174 
/ all cells). The cell number counting was done in 4 fields, at ×100 magnification, and 175 
averaged. 176 
Western blot analysis and protein kinase inhibitor assay 177 
 All cells were incubated in 1 mL of CBM containing 10% FBS on 2 × 2 cm 178 
stretch chambers. After 24 h, the medium was changed to serum-free MEMα, and the 179 
cells were incubated overnight. For western blot analysis, cells were stretched by CTS 180 
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(0.5 Hz, 10% elongation) for 30 min using the ST-140-10 system with or without HDAC 181 
inhibitors (TSA: 10 nM, MS-275: 100 nM). Cell lysates (10 µg of total protein/lane, 15 182 
µg/lane for RUNX-2 and phospho-RUNX-2) were subjected to sodium dodecyl sulfate-183 
polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% gel and then transferred 184 
onto polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA). 185 
The membranes were incubated with blocking reagent (TOYOBO) and incubated 186 
overnight at 4°C with anti-p38, ERK1/2, JNK MAPK, RUNX-2 (Abnova, Taipei, 187 
Taiwan), anti-phospho-p38, p44/42, JNK MAPK (Cell Signaling Technology, Beverly, 188 
MA, USA), anti-phospho-RUNX-2 (Cell Signaling Technology), histone H3, and acetyl-189 
histone H3 (Lys9) (Cell Signaling Technology) antibodies at a dilution of 1:1000 (1:2000 190 
for phospho-p38, histone H3, and acetyl-histone H3) in CanGet Signal Immunoreaction 191 
Enhancer Solution (TOYOBO). After washing, the membranes were stained with the 192 
appropriate horseradish peroxidase-conjugated anti-mouse secondary antibody (diluted 193 
1:10000, R&D Systems) or anti-rabbit secondary antibody (diluted 1:10000, Bethyl 194 
Laboratories, Montgomery, TX, USA) at room temperature for 1 h. We detected 195 
immunoreactive proteins using the Enhanced Chemiluminescence (ECL) Detection 196 
System (GE Healthcare, Buckinghamshire, UK). 197 
Statistical analysis 198 
All data were expressed as the means ± 95% confidence intervals (CI). All 199 
experiments were repeated at least 5 times and similar results were acquired. Differences 200 
among groups were analyzed using a one-way analysis of variance (ANOVA) with 201 
Bonferroni post-hoc test (SPSS Inc., Chicago, IL, USA). A P-value < 0.05 was considered 202 
statistically significant.  203 
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Results 204 
HDAC inhibitors have an effect on the viability of cultured human chondrocytes  205 
Both TSA and MS-275, at concentrations of 500 nM, inhibited chondrocytic 206 
proliferation to about 50% (Table. 2). MS-275 concentrations of 10 and 100 nM and TSA 207 
concentration of 10 nM did not reduce cell proliferation. The results of western blotting 208 
confirmed that histone H3 was acetylated by TSA or MS-275 at 10, 100, 500 nM 209 
concentrations without CTS (Supplemental Fig. 2).   210 
HDAC inhibitors upregulate COL2A1 and downregulate CTS-induced RUNX-2, 211 
ADAMTS-5, and MMP-3 gene expression 212 
The human chondrocytes used in this study continued to express type II collagen, 213 
even though they were grown in monolayers. COL2A1 expression in human 214 
chondrocytes was decreased by CTS and increased after treatment with 10 nM of TSA 215 
and 100 nM of MS-275. These effects were not noted after 100 nM or 500 nM of TSA 216 
treatment, and COL2A1 expression was downregulated by 500 nM of MS-275. RUNX-217 
2, ADAMTS-5, MMP-3, and MMP-13 expressions were upregulated by CTS and CTS-218 
induced expression of RUNX-2, ADAMTS-5, and MMP-3 were downregulated by TSA 219 
or MS-275 at concentrations of 10, 100, 500 nM (Fig. 1). CTS-induced expression of 220 
MMP-13 was downregulated by MS-275 at concentrations of 10, 100, 500 nM. These 221 
results lead us to perform subsequent experiments with TSA at 10 nM and MS-275 at 100 222 
nM. 223 
The results of real-time PCR showed that COL2A1 expression was increased by 224 
10 nM of TSA and 100 nM of MS-275, regardless of CTS addition. CTS-induced 225 
upregulation of RUNX-2, ADAMTS-5, and MMP-3 were significantly downregulated by 226 
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the treatment with 10 nM of TSA and 100 nM of MS-275. Treatment of the cells by 10 227 
nM of TSA and 100 nM of MS-275 without CTS did not affect the expression of RUNX-228 
2, ADAMTS-5, and MMP-3 (Fig.2A-D). These results were confirmed using human 229 
chondrocyte-like cells (SW1353) and NHAC-kn cells from an 18-year-old male, and 230 
obtained similar results (data not shown). MMP-13 expression tended to be upregulated 231 
by CTS and downregulated by HDAC inhibitors, however, the differences were not 232 
significant (Fig. 2E).  233 
HDAC inhibitors suppress CTS-induced increases in RUNX-2 and ADAMTS-5 protein 234 
expression 235 
RUNX-2 expression was upregulated and localized to the nucleus following CTS 236 
without HDAC inhibitors, but was not upregulated by incubation with HDAC inhibitors 237 
(Fig. 3A, RUNX-2, green signals). Similarly, ADAMTS-5 expression was upregulated 238 
and localized in the cytoplasm after CTS without HDAC inhibitors, but was not 239 
upregulated with HDAC inhibitors (Fig. 3A, ADAMTS-5, green signals). The positive 240 
cell ratios for RUNX-2 and ADAMTS-5 after CTS without HDAC inhibitors were 70.3 241 
± 10.5% and 67.4 ± 10.6%, respectively. The positive cell ratios in the other models were 242 
< 9.1 ± 7.1%. 243 
HDAC inhibitors regulate the activation of RUNX-2 in human chondrocytes  244 
We investigated the change in RUNX-2 phosphorylation with and without HDAC 245 
inhibitors by western blotting. RUNX-2 phosphorylation increased after CTS and was 246 
significantly suppressed by HDAC inhibitors (P < 0.001) (Fig. 4).  247 
HDAC inhibitors regulate the activation of MAPK in human chondrocytes 248 
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Mechanical stress can activate stress response signaling pathways, such as MAPK. 249 
Thus, we investigated MAPK phosphorylation (p38, JNK, and ERK) with and without 250 
HDAC inhibitors after CTS by western blotting. CTS significantly increased the 251 
phosphorylation of ERK and p38 at 60 min compared to the non-stretched controls (P < 252 
0.001) (Fig. 5A, C). HDAC inhibitors significantly inhibited the mechanical stress-253 
induced phosphorylation of ERK and p38 (P < 0.001). JNK phosphorylation tended to 254 
increase compared to non-stretched controls (P = 0.158) and was inhibited by HDAC 255 
inhibitors (TSA: P < 0.001, MS-275: P = 0.534) (Fig. 5B). 256 
  257 
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Discussion 258 
Chondrocytes are responsive to mechanical stress at both the protein and mRNA 259 
levels. During normal movement, articular cartilage experiences compression loads of up 260 
to 15%, which results in up to a 5% increase in chondrocytic elongation [30]. Although 261 
chondrocytes are directly compressed during the loading of normal cartilage, it is very 262 
probable that the matrix components of the ECM network, which are connected to the 263 
chondrocytes, stretch the cells during compression of cartilage [31].  264 
It is clear that the protein catabolic enzymes, such as MMPs and ADAMTSs, play 265 
important roles in the degradation of cartilage. MMPs and ADAMTS inhibitors do not 266 
have an obvious beneficial effect on OA due to side effects, such as ostealgia, myalgia, 267 
and tendovaginitis [32]. Therefore, the upstream regulators of these enzymes are 268 
potentially key candidates for the targeted OA therapy. However, the regulatory 269 
mechanisms of mechanical stress on these enzymes are largely unknown.  270 
The ADAMTS-5 promoter has a RUNX-2 binding site [33], suggesting that 271 
ADAMTS-5 is a potential downstream target of RUNX-2. Our report has shown that 272 
RUNX-2 is an upstream regulator of the mechanical stress-induced ADAMTS-5, 273 
suggesting that RUNX-2 could be a target gene in matrix degradation [17]. 274 
HDAC inhibitors have been investigated as anti-cancer compounds, largely by 275 
virtue of their influence on the cell cycle and apoptosis in transformed cells [34]. Recent 276 
reports suggested the efficacy of HDAC inhibitors as a therapy for arthritis. The action of 277 
HDAC inhibitors on cytokine-induced chondrocyte gene expression was first 278 
demonstrated by Young et al. [35], who reported that the interleukin (IL)-1α/oncostatin 279 
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M (OSM)-induced expressions of MMPs and ADAMTSs were suppressed by TSA in 280 
human chondrosarcoma cell lines and human chondrocytes. MMP-13 expression was 281 
reportedly controlled by MAPK through RUNX-2 activation [17, 36]. Furthermore, 282 
several reports showed that nuclear factor (NF)-κB pathways activated by IL-1 and tumor 283 
necrosis factor (TNF)-α regulated MMP-13 expression [37, 38]. In our study, CTS-284 
induced MMP-13 expression was not significantly downregulated by either HDAC 285 
inhibitors, nevertheless MAPK and RUNX-2 activation were suppressed. MMP-13 286 
expression was not upregulated significantly within 1 h after CTS, which is consistent 287 
with our previous result that significant MMP-13 upregulation was seen 12-24 h after 288 
CTS [17]. Hence, MMP-13 expression might be influenced by CTS-activated NF-κB 289 
pathways or other cytokines, and our experimental protocol in the current study to 290 
examine the early response to CTS might have failed to detect the later changes of MMP-291 
13 and the influence of HDAC inhibitors. 292 
In the present study, CTS-induced RUNX-2, ADAMTS-5, and MMP-3 mRNA 293 
expression were downregulated by treatment with HDAC inhibitors.  In contrast, 294 
treatment with HDAC inhibitors led to an upregulation of COL2A1 mRNA expression. 295 
Therefore, treatment with HDAC inhibitors can both decrease catabolic effects and 296 
increase anabolic effects. Huh et al. [39] reported HDAC-induced COL2A1 suppression 297 
in rabbit chondrocytes. Whereas, Furumatsu et al. [40] showed that HDAC enhanced 298 
COL2A1 expression in human chondrocytes. This discrepancy may be caused by species 299 
difference. We used human chondrocytes and our results were consistent with those of 300 
Furumatsu et al., who demonstrated that histones H3/H4 around the COL2A1 enhancer 301 
region were highly acetylated by HDAC inhibitor treatments by chromatin 302 
immunoprecipitation assays. HDAC inhibitor at concentrations of 500 nM decreased cell 303 
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proliferation by approximately half (Table 2). Hence, COL2A1 might be upregulated by 304 
TSA at a concentration of 10 nM or MS-275 at a concentration of 100 nM, while 305 
downregulated at higher concentrations probably by decreasing cell proliferation and 306 
viability.  307 
The MAPK pathway, involving p38, JNK, and ERK activity, has been shown to 308 
be modulated by diverse external stimuli, such as cytokines and physical stresses, which 309 
are transduced to the intracellular environment by mechanoreceptors [13, 41]. RUNX-2 310 
regulation by mechanical stress is thought to be mediated by specific MAPK pathways 311 
[16, 17, 42-44]. In particular, MEK/ERK signaling showed a strong correlation between 312 
cell surface integrin activation and subsequent stimulation of RUNX-2-dependent 313 
transcription [11-13]. RUNX-2 activity is controlled by phosphorylation; another group 314 
demonstrated that RUNX-2 was phosphorylated by ERK1/2 and p38 in response to 315 
mechanical stress [16, 17]. We previously reported that p38 was phosphorylated by 316 
mechanical stress in a human chondrosarcoma cell line (SW1353) [17]. Here, we 317 
demonstrated that ERK1/2, p38, and JNK were phosphorylated by mechanical stress in 318 
human chondrocytes. This discrepancy may be explained by cell type differences. 319 
Previous studies suggested that HDAC inhibitors regulate the MAPK pathway in 320 
several cancer cell lines [45-48]. It was reported that phosphorylation of ERK and JNK 321 
was decreased following the treatment of human K562 leukemia cells with butyrate [48]. 322 
Another report showed that valproic acid (VPA) and TSA blocked ERK and Akt 323 
activation in mouse C3H10T1/2 fibroblasts and that TSA also downregulated JNK 324 
phosphorylation [47]. In Ras-transformed 10T1/2 cells, Fecteau et al. [49] showed that 325 
the HDAC inhibitor FR901228 also suppressed the ERK and p38 pathways. Therefore, 326 
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HDAC inhibitors can modulate a number of intracellular signaling cascades in response 327 
to mechanical stress in human normal chondrocytes. The current study demonstrated that 328 
HDAC inhibitors reduced CTS-induced phosphorylation of ERK1/2, p38, and JNK in 329 
human chondrocytes. These findings suggested that HDAC inhibitors suppress RUNX-2 330 
and ADAMTS-5 expression by downregulating MAPK signaling. Therefore, the current 331 
study is the first to demonstrate that HDAC inhibitors decrease mechanical stress-induced 332 
MAPK phosphorylation and the resulting catabolic effects; however, the precise 333 
mechanism of this decrease remains unknown. Previous reports have suggested that 334 
HDAC inhibitors induce apoptosis in several types of tumor cells through cell cycle arrest 335 
mediated by the cyclin-dependent kinase (CDK) inhibitor p21WAF1/Cip1 [20-22, 50-52]. 336 
We previously showed that HDAC inhibitors increase the expression of the CDK 337 
inhibitors p16 and p21 [24]. Other groups have reported that p21 suppressed p38 activity 338 
and reduced the secretion of proinflammatory cytokines in Toll-like receptor-stimulated 339 
macrophages [53] and that p21 suppressed JNK activity and the IL-1-triggered activation 340 
of IL-6, IL-8, MCP-1, MIP-3α, MMP-1 and -3 in rheumatoid synovial fibroblasts [54]. 341 
These results suggested that the activation of CDK inhibitors by HDAC inhibitors may 342 
contribute to the suppression of the MAPK pathway.  343 
There are several limitations in the current study. First, the stretch system was a 344 
simple experimental model for OA in vitro experiments using cells in a monolayer; 345 
however, it remains unknown if HDAC inhibitors influence chondrocytes cultured in 346 
three dimensions and the efficacy of HDAC inhibitors for articular cartilage protection in 347 
vivo. Second, it was not clear which HDAC is the therapeutic target for cartilage 348 
degradation. Based on the result that both TSA and MS-275 showed inhibitory effects on 349 
the mechanical stress-induced expression of catabolic enzymes, it is reasonable to 350 
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consider that the therapeutic candidates are included in class I HDACs, such as HDAC 1, 351 
2, 3, and 8. Third, further investigations are required to demonstrate the efficacy of HDAC 352 
inhibitors using in vivo experiments with an animal OA model of cartilage destruction.  353 
In conclusion, the results of the current study demonstrated that HDAC inhibitors 354 
may function as potent repressors of the expression of matrix-degrading proteases, such 355 
as ADAMTS-5 and MMP-3, induced by mechanical stress via the inhibition of RUNX-2 356 
and the activation of MAPK in chondrocytes.  357 
  358 
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Gene Nucleotide sequence NCBI Gene No. 
Annealing 
Tm 
COL2A1 
F AAT TCC TGG AGC CAA AGG AT 
NM_ 
001844 55°C 
R AGG ACC AGT TGC ACC TTG AG 
RUNX-2 
F CTC TAC CAC CCC GCT GTC TT 
NM_ 
004348 55°C 
R CAC CTG CCT GGC TCT TCT TAC 
ADAMTS-5 
F TAT GAC AAG TGC GGA GTA TG 
NM_ 
007038 60°C 
R TTC AGG GCT AAA TAG GCA GT 
MMP-3 
F ATG CCC ACT TTG ATG ATG ATG AAC 
NM_ 
002422 60°C 
R CCA CGC CTG AAG GAA GAG ATG 
MMP-13 
F ACC CTG GAG CAC TCA TGT TTC CTA 
NM_ 
002427  
60°C 
 
R TGG CAT CAA GGG ATA AGG AAG GGT 
G3PDH 
F CAT CAA GAA GGT GGT GAA GCA G 
NM_ 
002046 60°C 
R CGT CAA AGG TGG AGG AGT GG 
Table 1 
The effects of TSA and MS-275 on the viability of human chondrocytes  
as determined by the MTT assay 
CTS - + + + + + + + 
TSA - - 10 - 100 - 500 - 
MS-275 - - - 10 - 100 - 500 
Mean folds 
of control 1.00 1.23* 1.11* 1.33* 0.88* 1.37* 0.54* 0.56* 
95% CI 
1.16 
- 
1.30 
1.03 
- 
1.18 
1.25 
- 
1.40 
0.80 
- 
0.95 
1.29 
- 
1.44 
0.46 
- 
0.61 
0.49  
- 
0.63 
Table 2 
The data are presented as the mean with 95% confidence intervals (CI) of  
6 times determinations. *P < 0.01, relative to CTS (-) and HDAC inhibitors (-). 
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